HighTower Advisors’s Argos Therapeutics, Inc. ARGS Stock Holding History

HighTower Advisors’s Portfolio ARGS Stock Details ARGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-1,604	Closed	-$5K	–	2454
2017 Q3	$5K	Hold	1,604	–	–	﹤0.01%	2173
2017 Q2	$11K	Buy	1,604 +275	+21%	+$2.34K	﹤0.01%	2113
2017 Q1	$11K	Hold	1,329	–	–	﹤0.01%	2007
2016 Q4	$130K	Buy	1,329 +25	+2%	+$2.34K	﹤0.01%	1749
2016 Q3	$129K	Hold	1,304	–	–	﹤0.01%	1716
2016 Q2	$160K	Hold	1,304	–	–	﹤0.01%	1540
2016 Q1	$167K	Hold	1,304	–	–	﹤0.01%	1840
2015 Q4	$60K	Hold	1,304	–	–	﹤0.01%	1885
2015 Q3	$126K	Buy	+1,304	New	+$154K	﹤0.01%	1711
2015 Q2	–	Sell	-1,479	Closed	-$263K	–	1858
2015 Q1	$263K	Buy	1,479 +229	+18%	+$39.8K	﹤0.01%	1312
2014 Q4	$250K	Hold	1,250	–	–	﹤0.01%	1309
2014 Q3	$252K	Buy	+1,250	New	+$195K	﹤0.01%	1279

Other funds holding ARGS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return

SMH

Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

KeyBank National Association Cleveland, Ohio $27.4B AUM 24.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

HighTower Advisors's ARGS Position: Q4 2017 in Review

HighTower Advisors sold out of Argos Therapeutics, Inc. (ARGS) in Q4 2017, closing a stake of 1,604 shares — an estimated $5K sold.

HighTower Advisors first reported a position in ARGS in Q3 2014 and held it in 12 quarters. The position peaked at $263K in Q1 2015. 28 funds tracked by Wall St. Rank hold ARGS as of Q4 2017.

HighTower Advisors reported no remaining Argos Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
HighTower Advisors sold 1,604 Argos Therapeutics, Inc. shares in Q4 2017, an estimated $5K.
HighTower Advisors first reported a position in Argos Therapeutics, Inc. in Q3 2014 and held it in 12 quarters.
HighTower Advisors's Argos Therapeutics, Inc. position peaked at $263K in Q1 2015.
28 funds tracked by Wall St. Rank held Argos Therapeutics, Inc. as of Q4 2017.

Based on HighTower Advisors's 13F filing for Q4 2017, filed 14 Feb 2018.